Faron Pharmaceuticals Oy Update on the Phase III INTEREST trial
May 11 2018 - 2:31AM
RNS Non-Regulatory
TIDMFARN
Faron Pharmaceuticals Oy
11 May 2018
Faron Pharmaceuticals Ltd
("Faron" or the "Company")
Update on the Phase III INTEREST trial of Traumakine in the
treatment of ARDS
TURKU - FINLAND, 11 May 2018 - Faron Pharmaceuticals Ltd
("Faron") (AIM: FARN), the clinical stage biopharmaceutical
company, today issues the following update on its Phase III
INTEREST trial of Traumakine in the treatment of ARDS. Since its
announcement on 8 May 2018, Faron has been conducting an initial
review of additional data from the Phase III INTEREST trial with
Traumakine.
Early analysis of certain biomarker indicators suggest that the
treatment did not produce the expected interferon-beta bioactivity
in the treatment group that was previously seen in Faron's Phase
I/II trial for Traumakine.
It is still too early to understand why this is the case and
there are a number of possible causes that the Company are
investigating including, inter alia, formulation, administration
and deactivation. Further detailed analysis of the data and testing
of product batches still needs to be conducted, and therefore there
is no guarantee that this will ultimately prove to be conclusive
or, of the resultant implications of that analysis.
Faron will provide an update with further information in due
course.
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey
Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com
Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500
About Faron Pharmaceuticals Ltd
Faron (AIM:FARN) is a clinical stage biopharmaceutical company
developing novel treatments for medical conditions with significant
unmet needs. The Company currently has a pipeline focusing on acute
organ traumas, vascular damage and cancer immunotherapy. The
Company's lead candidate Traumakine, to prevent vascular leakage
and organ failures, has completed a Phase III clinical trial in
Acute Respiratory Distress Syndrome (ARDS). An additional European
Phase II Traumakine trial is underway for the Rupture of Abdominal
Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a
ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has
the ability to switch immune suppression to immune activation in
various conditions, with potential across oncology, infectious
disease and vaccine development. This novel macrophage-directed
immuno-oncology switch called Tumour Immunity Enabling Technology
("TIET") may be used alone or in combination with other immune
checkpoint molecules for the treatment of cancer patients. Faron is
based in Turku, Finland. Further information is available at
www.faron.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFLFEFIILIT
(END) Dow Jones Newswires
May 11, 2018 02:00 ET (06:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024